Related Experiment Videos
Therapeutic antibodies elicited by immunization against TNF-alpha
I Dalum1, D M Butler, M R Jensen
1M&E Biotech A/S, Hørsholm, Denmark.
Nature Biotechnology
|July 15, 1999
Summary
This study presents a novel vaccination method to generate antibodies against tumor necrosis factor-alpha (TNF-alpha), a key factor in chronic inflammation. This approach effectively reduced symptoms in animal models of inflammatory diseases.
Area of Science:
- Immunology
- Inflammation Research
- Vaccine Development
Background:
- Tumor necrosis factor-alpha (TNF-alpha) plays a crucial role in the development of chronic inflammatory conditions.
- Current treatments for diseases like rheumatoid arthritis and Crohn's disease involve monoclonal antibodies targeting TNF-alpha.
Purpose of the Study:
- To develop a novel active immunization strategy against self TNF-alpha.
- To investigate the potential of a TNF-alpha vaccine for treating chronic inflammatory diseases.
Main Methods:
- Developed modified recombinant TNF-alpha molecules incorporating foreign T-helper epitopes.
- Administered these modified molecules to mice to induce a T-cell-dependent autoantibody response against TNF-alpha.
- Assessed the impact of immunization on experimental cachexia and collagen-induced arthritis models.
Main Results:
- Achieved a sustainable, polyclonal autoantibody response against TNF-alpha that waned upon cessation of booster injections.
- Demonstrated significant amelioration of symptoms in mouse models of experimental cachexia and type II collagen-induced arthritis.
- Confirmed the T-cell-dependent nature of the induced autoantibody response.
Conclusions:
- Vaccination against TNF-alpha using modified antigens is a feasible and effective strategy.
- This approach holds promise as a potential therapeutic option for rheumatoid arthritis and other chronic inflammatory diseases.
- The induced autoantibody response is controllable and sustainable.